keyword
MENU ▼
Read by QxMD icon Read
search

Hepatic arterial infusion chemotherapy

keyword
https://www.readbyqxmd.com/read/28810886/factors-affecting-survival-after-concurrent-chemoradiation-therapy-for-advanced-hepatocellular-carcinoma-a-retrospective-study
#1
Ja Kyung Kim, Jun Won Kim, Ik Jae Lee, Seung-Moon Joo, Kwang-Hun Lee, Eun-Suk Cho, Jeong-Sik Yu, Tae Joo Jeon, Yonsoo Kim, Jung Il Lee, Kwan Sik Lee
BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess the factors affecting survival after CCRT, including additional TACE during repeated HAIC. METHODS: Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively...
August 15, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28728985/adjuvant-hepatic-arterial-infusion-chemotherapy-is-beneficial-for-selective-patients-with-hepatocellular-carcinoma-undergoing-surgical-treatment
#2
Jui-Hu Hsiao, Cheng-Chung Tsai, Tsung-Jung Liang, Chia-Ling Chiang, Huei-Lung Liang, I-Shu Chen, Yu-Chia Chen, Po-Ming Chang, Nan-Hua Chou, Being-Whey Wang
BACKGROUND: Recurrence rate after curative surgical resection of Hepatocellular carcinoma (HCC) remains high. Postoperative hepatic arterial infusion chemotherapy (HAIC) has been suggested to improve survival. This study is to investigate the efficacy of HAIC in the patients with poor tumor factors such as vascular invasion or multiplicity. METHODS: From 2006 to 2014, 221 patients with HCC undergoing hepatectomy and pathologically staged as ≧ T2 (American Joint Committee on Cancer TNM staging system, 7th edition) were included...
July 17, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28705491/proposal-of-selection-criteria-for-operative-resection-of-hepatocellular-carcinoma-with-inferior-vena-cava-tumor-thrombus-incorporating-hepatic-arterial-infusion-chemotherapy
#3
Yosuke Kasai, Etsuro Hatano, Satoru Seo, Kojiro Taura, Kentaro Yasuchika, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto
BACKGROUND: Because operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus has been associated with a substantial risk of recurrence and postoperative morbidity, adequate patient selection for resection is necessary. Our aim was to propose selection criteria for resection of hepatocellular carcinoma with inferior vena cava tumor thrombus. METHODS: Long-term outcomes were analyzed retrospectively in 39 operative cases of hepatocellular carcinoma with inferior vena cava tumor thrombus (1996-2015)...
July 10, 2017: Surgery
https://www.readbyqxmd.com/read/28685137/effect-of-double-platinum-agents-combination-of-miriplatin-transarterial-oily-chemoembolization-and-cisplatin-hepatic-arterial-infusion-chemotherapy-in-patients-with-hepatocellular-carcinoma-report-of-two-cases
#4
Kohei Ogawa, Kenya Kamimura, Yukari Watanabe, Yosuke Motai, Daisuke Kumaki, Ryoya Seki, Akira Sakamaki, Satoshi Abe, Hirokazu Kawai, Takeshi Suda, Satoshi Yamagiwa, Shuji Terai
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third highest cause of cancer-associated mortality worldwide. The treatment of HCC is complicated by its variable biological behavior and the frequent coexistence of chronic liver disease, particularly cirrhosis. To date, multiple treatment modalities have been developed according to the stage of the tumor and the hepatic functional reserve, including transarterial treatments such as transarterial chemoembolization, transarterial oily chemoembolization (TOCE), and hepatic arterial infusion chemotherapy (HAIC)...
June 16, 2017: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/28676383/hepatectomy-after-down-staging-of-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus-using-chemoradiotherapy-a-retrospective-cohort-study
#5
Michinori Hamaoka, Tsuyoshi Kobayashi, Shintaro Kuroda, Hiroshi Iwako, Sho Okimoto, Tomoki Kimura, Hiroshi Aikata, Yasushi Nagata, Kazuaki Chayama, Hideki Ohdan
BACKGROUND: This study evaluates the survival benefit and safety of hepatectomy after down-staging by 3-dimensional conformal radiation therapy (3D-CRT) for major portal vein tumor thrombus (PVTT) combined with hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC). METHODS: Fifty-two patients with unresectable advanced HCC treated with HAIC combined with 3D-CRT for PVTT, from January 2002 to March 2015, were analyzed in this retrospective study...
July 1, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28656680/evaluation-of-the-assessment-for-continuous-treatment-with-hepatic-arterial-infusion-chemotherapy-scoring-system-in-patients-with-advanced-hepatocellular-carcinoma
#6
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
AIM: Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. However, hepatic arterial infusion chemotherapy (HAIC) is a treatment option in Asia. We recently developed the assessment for continuous treatment with HAIC (ACTH) score to guide decision-making for continuous HAIC treatment. The purpose of this study was to validate the utility of the ACTH score in a dedicated cohort. METHODS: One hundred and thirty-one patients with advanced HCC were enrolled in this study (90 in the training group and 41 in the validation group)...
June 28, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28652782/hepatic-artery-infusion-chemotherapy-improved-survival-of-hepatocellular-carcinoma-after-radical-hepatectomy
#7
Min Feng, Chengwu Tang, Wenming Feng, Ying Bao, Yinyuan Zheng, Jianbin Shen
OBJECTIVE: To evaluate the effect of postoperative hepatic artery-infusion chemotherapy (HAIC) on survival probability in patients with hepatocellular carcinoma (HCC) after radical hepatectomy. PATIENTS AND METHODS: This retrospective study included 85 patients with HCC who received radical hepatectomy from May 2005 to May 2010. Among these patients, 42 underwent two sessions of HAIC (5-fluoruracil [1,000 mg/m(2)], oxaliplatin [85 mg/m(2)], and mitomycin-C [6 mg/m(2)]) after radical hepatectomy (HAIC group), and 43 underwent radical hepatectomy only (the control group)...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28646261/hepatic-arterial-infusion-chemotherapy-for-extensive-liver-metastases-of-breast-cancer-efficacy-safety-and-prognostic-parameters
#8
Mitra Tewes, Michael Wilhelm Peis, Simon Bogner, Jens M Theysohn, Marcus Paul Reinboldt, Martin Schuler, Anja Welt
PURPOSE: Hepatic arterial infusion chemotherapy (HAIC) is an option for patients with liver-predominant metastatic breast cancer (LMBC), when no further systemic treatment is available. But systematic reports are limited. Here we conducted a retrospective analysis of LMBC patients treated at an expert center. METHODS: Individual patient data were retrieved from the clinical data base of the West German Cancer Center. Primary endpoints included hepatic response (RECIST), progression-free survival (PFS), overall survival (OS), and toxicity...
June 23, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28643305/-interventional-therapy-of-colorectal-liver-metastasis
#9
Qi Zhang, Gaojun Teng
Colorectal liver metastasis (CRLM) is one of the most difficult and key points in the treatment of colorectal cancer. Approximately 50% to 60% of patients diagnosed as colorectal cancer develops metastasis, and 80% to 90% of CRLM is unresectable. Surgical resection is the first-line treatment for CRLM, while it is only suitable for about 15% patients. Systemic chemotherapy can prolong the survival of CRLM patients, however, a part of CRLM patients are resistant to chemotherapy. With the development of technology and the update of clinical evidence, individual therapy with target drugs and multidisciplinary treatment (MDT) have became a tendency, and minimally invasive interventional therapy has gained more acceptance in the MDT mode of the treatment for CRLM...
June 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28638789/multidisciplinary-approach-of-colorectal-cancer-liver-metastases
#10
REVIEW
Giammaria Fiorentini, Donatella Sarti, Camillo Aliberti, Riccardo Carandina, Andrea Mambrini, Stefano Guadagni
Large bowel cancer is a worldwide public health challenge. More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases. Selection criteria for early diagnosis, chemotherapy and surgery have been recently expanded. The definition of resectability remains unclear. The presence of metastases is the most significant prognostic factor. For this reason the surgical resection of hepatic metastases is the leading treatment. The most appropriate resection approach remains to be defined...
June 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28626734/beneficial-effect-of-maintaining-hepatic-reserve-during-chemotherapy-on-the-outcomes-of-patients-with-hepatocellular-carcinoma
#11
Takeshi Terashima, Tatsuya Yamashita, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Hepatocellular carcinoma (HCC) usually develops in chronically damaged liver. We investigated hepatic reserves during chemotherapy of patients with advanced HCC and compensated liver function to evaluate the effect on patients' outcomes of maintaining hepatic reserve after chemotherapy. We retrospectively reviewed the medical records of 190 patients with Child-Pugh A with advanced HCC who were treated with sorafenib or hepatic arterial infusion chemotherapy (HAIC). We investigated the Child-Pugh score and albumin-bilirubin grade for hepatic reserve, and evaluated the effect of the change in Child-Pugh scores on patients' outcomes...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/28618075/surgical-treatment-for-advanced-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#12
REVIEW
Kazuhiko Sakamoto, Hiroaki Nagano
The Barcelona Clinic Liver Cancer (BCLC) staging system recommends administration of a tyrosine kinase inhibitor (sorafenib) as standard therapy in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). Sorafenib has been shown to prolong median overall survival (OS) by about 3 months in advanced HCC patients with PVTT (8.1 vs 4.9 months). However, its clinical effectiveness is still controversial and standard treatment with sorafenib is not established in Japan. Surgical resection is considered as a potentially curative treatment and provides an acceptable outcome for carefully selected patients...
June 15, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28555325/erratum-to-serum-hmgb1-concentrations-at-4%C3%A2-weeks-is-a-useful-predictor-of-extreme-poor-prognosis-for-advanced-hepatocellular-carcinoma-treated-with-sorafenib-and-hepatic-arterial-infusion-chemotherapy
#13
Kazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, Tomokazu Kawaoka, C Nelson Hayes, Yuji Teraoka, Kana Daijo, Yuki Nakamura-Inagaki, Kei Morio, Hatsue Fujino, Hiromi Kan, Takuro Uchida, Keiichi Masaki, Tomoki Kobayashi, Takashi Nakahara, Grace Naswa Makokha, Yizhou Zhang, Yuko Nagaoki, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiromi Abe-Chayama, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki Chayama
No abstract text is available yet for this article.
May 29, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28537788/the-precision-of-hepatic-arterial-infusion-scintigraphy-as-a-quantitative-biomarker-of-tumor-microvasculature
#14
Mark Dunphy, Neeta Pandit-Taskar, Josef J Fox, Nancy Kemeny
OBJECTIVE: Optimal clinical development of new cancer therapies targeting tumor vasculature requires new target-specific response assays. This clinical study examined the test-retest repeatability of SPECT as an in vivo assay of angiogenic hepatic tumor microvasculature using an intraarterial infusion of (99m)Tc-macroaggregated albumin (MAA) delivered via a hepatic artery infusion (HAI) pump. MATERIALS AND METHODS: Patients with primary or secondary cancerous liver tumors with HAI pump-catheter implants placed for HAI chemotherapy underwent hepatic SPECT after separate arterial infusions of 37 and 185 MBq of (99m)Tc-MAA via an HAI pump...
July 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28508838/randomized-controlled-phase-iii-study-comparing-hepatic-arterial-infusion-with-systemic-chemotherapy-after-curative-resection-for-liver-metastasis-of-colorectal-carcinoma-jfmc-29-0003
#15
Mitsuo Kusano, Michitaka Honda, Koji Okabayashi, Koho Akimaru, Syuichi Kino, Yasushige Tsuji, Masashi Watanabe, Satoshi Suzuki, Takaki Yoshikawa, Junichi Sakamoto, Koji Oba, Shigetoyo Saji
BACKGROUND: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. METHODS: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF)...
January 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28490356/transhepatic-arterial-infusion-chemotherapy-using-a-combination-of-miriplatin-and-cddp-powder-versus-miriplatin-alone-in-the-treatment-of-hepatocellular-carcinoma-a-randomized-controlled-trial
#16
Kenya Kamimura, Takeshi Suda, Takeshi Yokoo, Hiroteru Kamimura, Tsutomu Kanefuji, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Nobuo Waguri, Satoshi Yamagiwa, Shuji Terai
BACKGROUND: Based on promising results from a Phase I study of hepatic arterial infusion chemotherapy using a combination of miriplatin and cisplatin powder (DDP-H) for unresectable hepatocellular carcinoma (UMIN-CTR000003541), a multicenter, open-label, randomized phase II study was conducted to evaluate the efficacy and safety of the combination therapy versus miriplatin monotherapy. METHODS: Nineteen patients, five and fourteen Barcelona-Clinic Liver Cancer staging classification A and B cases, respectively, were randomly assigned to receive either miriplatin monotherapy (n = 9) or miriplatin/DDP-H combination therapy (n = 10)...
May 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28474222/serum-hmgb1-concentrations-at-4%C3%A2-weeks-is-a-useful-predictor-of-extreme-poor-prognosis-for-advanced-hepatocellular-carcinoma-treated-with-sorafenib-and-hepatic-arterial-infusion-chemotherapy
#17
Kazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, Tomokazu Kawaoka, C Nelson Hayes, Yuji Teraoka, Kana Daijo, Yuki Nakamura-Inagaki, Kei Morio, Hatsue Fujino, Hiromi Kan, Takuro Uchida, Keiichi Masaki, Tomoki Kobayashi, Takashi Nakahara, Grace Naswa Makokha, Yizhou Zhang, Yuko Nagaoki, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiromi Abe-Chayama, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki Chayama
BACKGROUND: Biomarkers predicting the response to the anticancer treatment and prognosis in patients with advanced hepatocellular carcinoma (HCC) are required. Recently, high mobility group box 1 (HMGB1) was reported to promote HCC progression and be associated with poor prognosis for patients with HCC. The purpose of this study was to assess serum HMGB1 concentrations before and during sorafenib treatment or hepatic arterial infusion chemotherapy (HAIC) and to explore the ability of serum HMGB1 concentrations to predict prognosis...
May 4, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28433600/hepatic-arterial-infusion-chemotherapy-for-unresectable-liver-metastases-of-colorectal-cancer-a-multicenter-retrospective-study
#18
Annie Lim, Samuel Le Sourd, Hélène Senellart, Dominique Luet, Frédéric Douane, Christophe Perret, Antoine Bouvier, Sylvie Métairie, Estelle Cauchin, Philippe Rougier, Tamara Matysiak-Budnik, Yann Touchefeu
INTRODUCTION: Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. METHODS: Clinical, biological, and radiological data of patients treated with HAIC for unresectable LM from CRC in 4 institutions from October 2011 to January 2016 were retrospectively analyzed...
March 14, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28426374/perioperative-hepatic-arterial-infusion-pump-chemotherapy-is-associated-with-longer-survival-after-resection-of-colorectal-liver-metastases-a-propensity-score-analysis
#19
Bas Groot Koerkamp, Eran Sadot, Nancy E Kemeny, Mithat Gönen, Julie N Leal, Peter J Allen, Andrea Cercek, Ronald P DeMatteo, T Peter Kingham, William R Jarnagin, Michael I D'Angelica
Purpose To investigate whether perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with overall survival (OS) in patients who had a complete resection of colorectal liver metastases (CLM). Methods Patients who underwent a complete resection of CLM between 1992 and 2012 were included from a single-center prospectively maintained database. All patients who received HAI also received perioperative systemic chemotherapy. Propensity score analysis was used to match patients for seven known prognostic factors...
June 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28373752/prognostic-factors-for-transarterial-chemoembolization-combined-with-sustained-oxaliplatin-based-hepatic-arterial-infusion-chemotherapy-of-colorectal-cancer-liver-metastasis
#20
Hangyu Zhang, Jianhai Guo, Song Gao, Pengjun Zhang, Hui Chen, Xiaodong Wang, Xiaoting Li, Xu Zhu
OBJECTIVE: To investigate the prognostic factors in chemorefractory colorectal cancer liver metastasis (CRCLM) patients treated by transarterial chemoembolization (TACE) and sustained hepatic arterial infusion chemotherapy (HAIC). METHODS: Between 2006 and 2015, 162 patients who underwent 763 TACE and HAIC in total were enrolled in this retrospective study, including 110 males and 52 females, with a median age of 60 (range, 26-83) years. Prognostic factors were assessed with Log-rank test, Cox univariate and multivariate analyses...
February 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
keyword
keyword
84585
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"